Compare Citius Pharmaceuticals Inc (CTXR) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Toyota Motor Corp trades at $187.85 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 11936.5× Citius Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays a 3.32% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TM | |
|---|---|---|
Market Cap | $18.73M | $223.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $248.29 |
52-Week Low | $0.48 | $166.50 |
Enterprise Value | $14.95M | $417.39B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.
Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
